You are here

  • Home
  • Archive
  • Volume 11, Issue 5
  • Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial

Article metrics

Article menu

Download PDFPDF

Clinical/translational cancer immunotherapy
Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial

 

Online download statistics by month:

Online download statistics by month: May 2023 to March 2026

AbstractFullPdf
May 2023697702148
Jun 202344044235
Jul 202325726059
Aug 202320120954
Sep 202313513637
Oct 202312712742
Nov 202316616656
Dec 202318218352
Jan 202411611968
Feb 2024909253
Mar 202411811875
Apr 202414114187
May 202411311555
Jun 2024868543
Jul 202410410657
Aug 2024888735
Sep 2024787855
Oct 2024979761
Nov 202411711850
Dec 202427728263
Jan 202512312372
Feb 202517117170
Mar 202514814973
Apr 202520420692
May 202514414465
Jun 2025979751
Jul 2025110
Aug 2025550
Sep 202510100
Mar 2026110
Total453445701608